Cristina Moglia is currently Assistant Professor of Neurology at the Department of Neurosciences ‘Rita Levi Montalcini’ of the University of Turin. She has been working at the Turin ALS Expert Centre since 2006. Since 2006 she has been an active researcher in the neurological field, with a particular focus on ALS and other neuromuscular diseases; her scientific production is characterized by epidemiological, clinical genetics, neuroimaging and clinical trials, with more than 97 papers in peer reviewed international journals.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.